Royal Bank of Canada Cuts Stock Holdings in Penumbra, Inc. $PEN

Posted by on Aug 8th, 2026

Royal Bank of Canada trimmed its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 49.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,794 shares of the company’s stock after selling 39,656 shares during the period. Royal Bank of Canada’s holdings in Penumbra were worth $13,067,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Stephens Investment Management Group LLC bought a new position in shares of Penumbra in the 4th quarter worth $37,563,000. New York Life Investment Management LLC bought a new stake in shares of Penumbra during the 4th quarter worth $999,000. Simplify Asset Management Inc. grew its position in Penumbra by 89.7% in the fourth quarter. Simplify Asset Management Inc. now owns 15,827 shares of the company’s stock worth $4,921,000 after acquiring an additional 7,485 shares in the last quarter. SBI Okasan Asset Management Co.Ltd. purchased a new position in Penumbra in the fourth quarter worth $2,091,000. Finally, M&T Bank Corp increased its stake in Penumbra by 4,733.1% in the fourth quarter. M&T Bank Corp now owns 38,955 shares of the company’s stock valued at $12,111,000 after acquiring an additional 38,149 shares during the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Penumbra Stock Performance

Penumbra stock opened at $324.67 on Friday. The firm has a fifty day simple moving average of $318.84 and a two-hundred day simple moving average of $329.91. The company has a quick ratio of 3.86, a current ratio of 5.75 and a debt-to-equity ratio of 0.01. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $362.41. The company has a market capitalization of $12.79 billion, a PE ratio of 79.77, a P/E/G ratio of 2.01 and a beta of 0.70.

Penumbra (NYSE:PEN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). The company had revenue of $390.05 million for the quarter, compared to the consensus estimate of $389.64 million. Penumbra had a net margin of 10.67% and a return on equity of 10.50%. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period last year, the business posted $0.86 earnings per share. Research analysts expect that Penumbra, Inc. will post 5.02 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on PEN. Zacks Research lowered Penumbra from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Evercore reiterated an “outperform” rating and set a $320.00 price objective on shares of Penumbra in a research report on Monday, July 6th. Citigroup decreased their price objective on Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a report on Thursday, May 7th. Wall Street Zen upgraded Penumbra to a “hold” rating in a research report on Saturday, May 9th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Penumbra has a consensus rating of “Hold” and a consensus target price of $367.07.

Read Our Latest Stock Analysis on Penumbra

About Penumbra

(Free Report)

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.

Read More

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).

Institutional Ownership by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.